Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine versus sertraline for sleep quality in major depressive disorder
IRCT20260823070767N1Phase 3Completed
- Sponsor
- North Khorasan University of Medical Sciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in major depressive disorder (MDD) comparing Agomelatine with Sertraline (2 arms). Primary endpoint: Change in Pittsburgh Sleep Quality Index score from baseline to week 8. Started Mar 2026; status: completed.
02
Drugs
agomelatinesertraline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20260823070767N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260823070767N1.